Introduction
Chronic migraine (CM) [1] usually appears as a result of the worsening in frequency and intensity of pain in patients with episodic migraine. Patients suffering from CM experience great disability [2] [3] [4] . However, preventive treatments are still underdeveloped, with the exception of topiramate [5] [6] [7] .
OnabotulinumtoxinA is a treatment specifically approved for the prophylaxis of CM in adults. Its efficacy has been studied in two large multicentre randomized clinical trials -Phase III Research Evaluating Migraine Prophylaxis Treatment (PREEMPT) 1 and 2 [8, 9] , and several subsequent studies [10] [11] [12] [13] . Post-marketing research has found that most patients with CM maintain their response in the second year of treatment and may even be able to discontinue treatment [14] [15] [16] [17] [18] [19] [20] , also showing important improvements in quality-of-life measures [21, 22] and reduction in healthcare resource use and other medical costs related to migraine [23] . Several studies have looked for predictors of response to OnabotulinumtoxinA, either clinical features [10, [24] [25] [26] [27] [28] or molecular biomarkers [29, 30] , with controversial results.
The goal of this study was twofold: to assess the effectiveness of OnabotulinumtoxinA in CM after 1 year of treatment in a real-life setting and to identify clinical predictors of outcome. As secondary objectives we wanted to evaluate the impact of OnabotulinumtoxinA on measures of disability, medication intake and healthcare resource use.
Materials and methods

Study design
This was a prospective multicentre descriptive study.
Study participants
Patients were recruited between March 2014 and December 2015 in 13 hospitals in Spain.
Subjects were selected from those visiting Headache Clinics and fulfilling diagnostic criteria for CM [1] . They were considered to be eligible for treatment with OnabotulinumtoxinA after failure to respond to adequate trials of at least two prophylactic agents (reduction of headache days >50% at the minimum effective dose for at least 3 months), of which one was required to be topiramate, or after tolerability failure [31] . Overuse of abortive medication and continuation of oral prophylactic therapy were allowed. Exclusion criteria were those of treatment with OnabotulinumtoxinA.
The Research Ethics Committee of Servicio Galego de Sa ude approved the study. All patients provided written informed consent.
Subjects underwent a complete medical history and examination. Data on age, sex, duration of CM, type of migraine, analgesic overuse, symptomatic and preventive treatments, and concomitant diseases were collected from medical records. Number of headaches and migraines per month, unilaterality of pain and number of analgesics and triptans per month were determined based on patient recall from the previous month. Baseline migraine-related disability was measured using the Migraine Disability Assessment (MIDAS). Intensity of headache (as a mean of the last month's episodes) was measured based on reported score using a visual analogue scale.
Treatment
Subjects received intramuscular OnabotulinumtoxinA following the PREEMPT protocol [32] every 12 weeks, at 3, 6, 9 and 12 months.
Follow-up
Patients were asked to keep a paper diary during the 12-month follow-up. They recorded days of headache (longer than 1 h), days of migraine, maximum intensity of headache, symptomatic medication administered, any migraine-related use of the emergency room and days of disability. These data were collected at 3 and 12 months of treatment, when they also filled out the MIDAS questionnaire.
Data and statistical analysis
Statistical analysis was performed with IBM SPSS Statistics 20.0 software for Mac (SPSS Inc., Chicago, IL, USA) by a single blinded investigator (Y.L.). Mean values (AE SD) were calculated for continuous variables after the method of Kolmogorov-Smirnov was applied to confirm that the data were sampled from a Gaussian distribution. Categorical data were reported as percentages and compared by chi-square test. Paired t-test was used to compare differences between the main treatment effectiveness variables. After the OnabotulinumtoxinA effectiveness at 12 months variable was categorized, independent ttest was applied to assess differences between migraine-associated factors. Pearson correlation coefficient was used to analyse the association between migraine-associated factors and effectiveness at 12 months.
A receiver operating characteristic analysis was carried out to identify the best discriminant cut-off point for the mean time of CM duration in relation to response to treatment. A logistic regression analysis was performed to assess potential predictors of good outcome. OnabotulinumtoxinA effectiveness at 12 months was the dependent variable and those variables that were related to good response in the bivariate analysis were entered in the model. Significant difference was set at P < 0.05.
Results
A total of 725 patients completed the study; 622 patients (85.8%) were females. Mean age was 46.8 AE 12.0 years. A total of 542 patients were diagnosed with migraine without aura (74.8%). Mean time since the diagnosis of CM was 20.4 AE 18.7 months.
Additional baseline data are displayed in Table 1 . Thirty-two patients dropped out of the study during follow-up: seven subjects did not find treatment satisfactory (21.9%), five did not tolerate it (15.6%) and 20 (62.5%) were lost to follow-up.
Patients were stratified into four groups according to reduction of headache days per month: >75% (excellent responders), 50-75% (moderate responders), 25-50% and <25%. A total of 480 patients (66.2%) were responders at 3 months with 19.4% excellent responders. After 12 months of treatment, 575 patients (79.3%) were responders and 198 (27.3%) had an excellent response. Table 2 shows changes in baseline measures at 3 and 12 months of treatment. There was a reduction in headaches per month, migraine headaches per month, intensity of headache, use of abortive medication and other measures. The major change from baseline happened after the first injection of OnabotulinumtoxinA, although patients kept improving in the following months.
Only 12.3% of patients presented adverse events after the first injection of OnabotulinumtoxinA, of which 10.2% were mild. After 12 months, 94.9% of patients reported no adverse events.
When comparing baseline characteristics between responders (n = 575) and non-responders (n = 150), we found statistically significant differences for duration of CM, unilateral pain, use of combined symptomatic treatment, days of disability per month and intensity of headache measured using a visual analogue scale (Table 3 ). Correlation analysis of data showed that patients with a shorter duration of disease (r = À0.108; P = 0.004), fewer days of disability per month (r = À0.144; P = 0.001) and milder headache (r = À0.098; P = 0.008) had a greater chance of responding to treatment with OnabotulinumtoxinA. Conversely, we found a positive correlation between unilaterality of pain and effectiveness (r = 0.093; P = 0.012). Hypertension, heart disease, gastrointestinal disease, lung disease and skin disturbances. Data are given as n (%) or mean AE SD. Hypertension, heart disease, gut disease, lung disease and skin disturbances. Data are given as n (%) or mean AE SD.
The receiver operating characteristic analysis for duration of disease showed an area under the curve of 0.441 (95% confidence interval, 0.388-0.493; P = 0.025), suggesting that a duration of CM of <12 months predicted effectiveness with a sensitivity of 72% and a specificity of 78%. After categorizing duration of disease (<12 months and ≥12 months), a logistic regression model was performed using outcome as the dependent variable. Duration of CM <12 months reached statistical significance with an odds ratio of 1.470 (95% confidence interval, 1.123-2.174; P = 0.045) ( Table 4 ).
Discussion
Our study shows that treatment with OnabotulinumtoxinA is effective. More than 66% of patients respond to treatment after the first dose and the rate of response reaches 79.3% after 12 months. A drastic change in frequency and severity of headaches occurs just after the first dose of OnabotulinumtoxinA, although improvement continues with the following doses up to 1 year of treatment; repeated injections increase the number of patients who show an excellent response to treatment from 19.4% to 27.3%. These results highlight the importance of continuing treatment with OnabotulinumtoxinA beyond the first dose, even when it is not initially effective.
Treatment with OnabotulinumtoxinA also leads to improvements in secondary measures of effectiveness, such as use of abortive medication and MIDAS score, cutting down days of disability and visits to the emergency department. Decrease in MIDAS score occurs in a piecemeal way during the 12 months of treatment.
Since the results from PREEMPT trials were published in 2010 many post-commercialization studies have borne out the efficacy of OnabotulinumtoxinA in CM [13] [14] [15] [16] [17] [18] [19] . A prospective study including 254 patients [16] with endpoints similar to our study showed lower efficacy rates, perhaps because their patients had already tried three different preventive treatments without response. Other studies found diverse rates of efficacy after treatment [13] [14] [15] 19] and some reflected a high rate of response after the first OnabotulinumtoxinA injection [17] . According to these studies, the first cycle of treatment produces the most dramatic drops in number and intensity of headaches as well as improvements in other significant measures [17, 20] , but findings regarding effects after 1 year of treatment are controversial [11, [17] [18] [19] . A multicentre study is currently ongoing to try to answer some of the clinical questions that remain unclear about long-term use (108 weeks) of OnabotulinumtoxinA in CM [33] .
In our sample, adverse events rates were lower than in previous studies [11] [12] [13] , with 87.7% of patients reporting no adverse events after the first dose, and the adverse events being mild in most cases (82.3%). Adverse events rate decreased over the months as could also be seen in the PREEMPT sample [8] [9] [10] [11] , suggesting that continued exposure improves tolerability and that cumulative toxicity does not occur.
In order to give a more complete view of the effect of treatment in our sample, we measured intake of abortive medication, disability days per month and use of emergency services as an indirect gauge of headache impact in patients' lives. These features show the economic and social burden of CM, and the economic impact of treatment with OnabotulinumtoxinA, which have already been investigated in previous studies [34] .
With regard to clinical predictors of effectiveness, we found a clear correlation between effectiveness and duration of CM, unilaterality of pain, days of disability per month and intensity of headache. From a clinical practice point of view, we want to stress the importance of duration of CM. Starting treatment with OnabotulinumtoxinA in the first year after CM diagnosis increases the chances of being a responder. The effect of duration of migraine has been previously demonstrated and different studies [13, 16, 27, 28] have stated that treatment with OnabotulinumtoxinA should be indicated in the early stage of the disease as this could lead to a better outcome [35] . Our results regarding intensity of headache and days of disability per month support this 'early-stage' approach; chances of improvement are higher, whereas pain is milder and therefore patients experience fewer days off regular activities. These findings are especially interesting as time from diagnosis to treatment is one of the few factors that can be controlled by clinicians. Our study has several limitations. The fact that this is a large multicentre study is one of its strengths, but can affect the uniformity of data. We relied on patient recall for pre-treatment number and intensity of headaches, which could have led to under-or overestimation. We did not assess several clinical features of migraine that have been previously reported as related to response to OnabotulinumtoxinA [25, 26] . We included patients with overuse of medication, as recommended by the International Headache Society [36] and given that OnabotulinumtoxinA has shown effectiveness in patients with overuse headache [37] [38] [39] [40] , but we did not stratify them accordingly or with other preventive medications. One limiting factor of treating patients 'too early' is that it is not possible to know whether the effect is due in part to a higher spontaneous resolution of CM in short-term patients.
Conclusion
In conclusion, this is a large multicentre study that shows high rates of effectiveness after 1 year of treatment with OnabotulinumtoxinA in patients with CM. Some clinical characteristics of patients were related to good outcome in our sample, such as unilateral pain, intensity of headache, days of disability per month and time since CM diagnosis. Given these results, we underline the importance of reducing time between CM diagnosis and onset of OnabotulinumtoxinA treatment in order to increase the chances of patients having an optimal response.
